Exciting Advances and Unanswered Questions with CAR T-Cell Therapy

In this segment, “Exciting Advances and Unanswered Questions with CAR T-Cell Therapy”, Marcela Maus, MD, PhD, and Frederick Locke, MD discuss exciting developments in CAR T-cell therapy. CAR T-cell therapies have proven to be highly effective in patients with leukemia and lymphoma.

Allogeneic CAR T-cell trials are showing similar response rates to those seen in early studies of autologous therapy, though longer follow-up is needed. Dual targeting may potentially combat mechanisms of resistance, which vary depending on the tumor type. The feasibility of administering CAR T-cell therapy in community centers and its utility in solid tumors are also discussed.
Previous Article Exciting Aspects in AML Therapies in 2021 and Beyond